Hot Flashes: Drugs That Cause or Treat Them (and Why You Get Them)

What Causes Hot Flashes?

Hot flashes arise from a narrowing of the hypothalamic thermoneutral zone. When estrogen levels fall, neurons in the arcuate nucleus that release neurokinin B (NKB) become overactive, triggering heat-dissipation responses (flushing, sweating, palpitations) at temperatures that would not normally provoke them. The core physiology is well-established in the literature [1].

The Hypothalamic Thermostat Mechanism

The arcuate nucleus contains a dense cluster of neurons co-expressing kisspeptin, NKB, and dynorphin, often called KNDy neurons. Estrogen normally suppresses NKB signaling. Remove that suppression and the thermoneutral zone shrinks to as little as 0.4°C, compared with roughly 2°C in premenopausal women [2]. Even minor core temperature fluctuations then set off the heat-loss cascade.

What Actually Happens During an Episode

A typical hot flash lasts 1 to 5 minutes. Skin temperature over the sternum rises by 1 to 7°C, heart rate increases by 7 to 15 beats per minute, and peripheral vasodilation produces visible flushing. Night sweats are the same process occurring during sleep, often fragmenting sleep architecture enough to produce measurable cognitive impairment the next day [3].

Who Gets Them and for How Long?

The Study of Women's Health Across the Nation (SWAN, N=3,302) found that median duration of frequent vasomotor symptoms was 7.4 years, and women who began experiencing symptoms before their final menstrual period had the longest duration, a median of 11.8 years [4]. African-American women reported the highest frequency and the longest duration of any racial or ethnic group in that cohort.

Drugs and Conditions That Cause or Worsen Hot Flashes

Several medications and clinical conditions directly precipitate hot flashes by disrupting estrogen signaling, altering central thermoregulation, or provoking vasomotor instability.

Hormone-Blocking Drugs

Tamoxifen and aromatase inhibitors. Tamoxifen, a selective estrogen receptor modulator (SERM) used in breast cancer treatment, causes hot flashes in 40 to 80% of users [5]. Aromatase inhibitors (anastrozole, letrozole, exemestane) suppress estrogen synthesis to near-zero in postmenopausal women, producing a more severe vasomotor burden than tamoxifen in head-to-head comparisons.

GnRH agonists and antagonists. Leuprolide, goserelin, and degarelix suppress ovarian or testicular sex hormone production via medical castration. Men on androgen deprivation therapy (ADT) for prostate cancer experience hot flashes at rates of 55 to 80%, and the symptoms can persist for months after stopping the drug [6].

Raloxifene. This SERM, prescribed for osteoporosis and breast cancer risk reduction, carries a black-box warning that includes increased risk of hot flashes. In the MORE trial (N=7,705), raloxifene users were 2.4 times more likely to report hot flashes than placebo users [7].

Opioids and Opioid Antagonists

Long-term opioid use suppresses hypothalamic GnRH pulsatility, producing opioid-induced androgen deficiency (OPIAD) and secondary hot flashes. Paradoxically, naltrexone and naloxone, which block opioid receptors, can precipitate acute withdrawal-like hot flashes in opioid-dependent individuals and occasionally in opioid-naive users as well.

Antidepressants

Venlafaxine and fluoxetine are sometimes prescribed to reduce hot flashes, yet in certain patients, especially those newly starting therapy, serotonin surges may initially worsen flushing. Bupropion has been reported in case series to trigger new-onset hot flashes, likely through norepinephrine reuptake inhibition and resultant vasomotor instability.

Other Triggers Worth Knowing

• Niacin (nicotinic acid): Prostaglandin D2-mediated cutaneous flushing, distinct from true thermoregulatory hot flashes but clinically similar.
• Calcium channel blockers (especially nifedipine): Peripheral vasodilation can mimic or worsen flushing.
• Cyclosporine and tacrolimus: Reported to cause flushing in transplant recipients.
• Alcohol: Accelerates estrogen metabolism and directly dilates cutaneous blood vessels.

Drugs That Treat Hot Flashes

Estrogen-Based Hormone Therapy: The Reference Standard

Systemic estrogen, with or without progestogen, remains the most effective pharmacological treatment for vasomotor symptoms. Across pooled data, estrogen-based hormone therapy (HT) reduces hot flash frequency by 75 to 90% and severity scores by a comparable margin [8].

Formulations and Doses

The FDA-approved options include oral 17-beta-estradiol (0.5 to 2 mg daily), transdermal patches (0.025 to 0.1 mg/day), gels, sprays, and vaginal rings with systemic absorption. Women with an intact uterus require concurrent progestogen to protect the endometrium. Micronized progesterone 200 mg (Prometrium) is the most physiological option and carries a more favorable cardiovascular signal than synthetic progestins in observational data from the E3N cohort (N=80,377) [9].

The WHI Context: Risk in Perspective

The Women's Health Initiative (WHI, N=16,608) is the trial most frequently cited to discourage HT use. The combined estrogen-plus-progestin arm found a hazard ratio of 1.26 for invasive breast cancer after 5.6 years [10]. What is frequently omitted: the estrogen-only arm (in hysterectomized women) showed a hazard ratio of 0.77 for breast cancer, and absolute risk differences were small. The North American Menopause Society (NAMS) 2023 Position Statement states: "For women aged younger than 60 years or who are within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for the treatment of bothersome vasomotor symptoms" [11].

Fezolinetant: The First Non-Hormonal Neurokinin-3 Antagonist

Fezolinetant (Veozah, Astellas) targets the NK3 receptor on KNDy neurons, blocking the NKB signal that triggers thermoregulatory responses. The FDA approved it in May 2023 based on the SKYLIGHT 1 and SKYLIGHT 2 trials.

SKYLIGHT Trial Data

In SKYLIGHT 1 (N=501), fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by 60% from baseline at week 12, compared with 40% for placebo (P<0.001) [12]. Severity scores improved by a comparable proportion. The drug carries a liver safety monitoring requirement: baseline LFTs and repeat testing at weeks 4 and 8, then periodically thereafter.

Who Is Fezolinetant For?

It is the first option approved specifically for women who cannot or choose not to use hormone therapy, including breast cancer survivors and women with thromboembolic history. Current contraindication: cirrhosis and end-stage renal disease.

Paroxetine 7.5 mg (Brisdelle): The Only FDA-Approved SSRI for Hot Flashes

Paroxetine 7.5 mg is lower than the antidepressant dose (20 to 60 mg) and was specifically formulated for vasomotor symptoms. In the key trial (N=591), active drug reduced mean hot flash frequency from 9.8 to 4.9 per day, versus 9.7 to 6.4 per day on placebo, representing approximately a 50% reduction versus 25% for placebo [13].

Prescribers should avoid paroxetine in women taking tamoxifen. Paroxetine is a strong CYP2D6 inhibitor and reduces tamoxifen conversion to its active metabolite endoxifen by up to 65%, potentially compromising cancer treatment.

Venlafaxine and Other SNRIs

Venlafaxine 75 mg extended-release is the most widely used off-label SNRI for hot flashes. A randomized crossover trial by Loprinzi et al. (N=102) showed a 61% reduction in hot flash score versus 27% placebo [14]. Desvenlafaxine and duloxetine show similar but slightly smaller effects in head-to-head data. All SNRIs carry the standard discontinuation-syndrome caution: taper rather than abrupt stopping.

Gabapentin

Gabapentin 300 mg three times daily reduces hot flash frequency by roughly 45% in placebo-controlled trials [15]. The FDA has not approved it for this indication, but it is recommended in NAMS guidelines as a second-line non-hormonal option. Sedation limits daytime use; some clinicians prescribe the full 900 mg dose at bedtime for patients whose primary complaint is night sweats.

Clonidine

Clonidine, an alpha-2 adrenergic agonist, reduces hot flash frequency by 15 to 37% in placebo-controlled studies, making it the least effective of the recognized non-hormonal options [16]. Orthostatic hypotension and dry mouth limit tolerability, particularly at doses above 0.1 mg twice daily. It remains a reasonable choice when other agents are contraindicated or not tolerated.

Oxybutynin

Oxybutynin, an anticholinergic primarily used for overactive bladder, reduced hot flash scores by 73% in the ACCPAC trial (N=150) at 15 mg daily, outperforming both placebo (29%) and gabapentin in a three-arm comparison [17]. Dry mouth (41% at 15 mg) is the primary dose-limiting side effect. The American College of Obstetricians and Gynecologists (ACOG) includes oxybutynin as an option in its 2023 clinical guidance on menopause management.

Megestrol Acetate and Other Progestins

Megestrol acetate 20 mg twice daily reduces hot flash frequency by 74 to 80% in placebo-controlled data [18]. Despite this efficacy, it is rarely used as a first-line agent because it is a synthetic progestogen with potential to stimulate hormone-sensitive tissues, and its safety in breast cancer survivors is debated. Medroxyprogesterone acetate 20 mg daily shows comparable efficacy.

A Decision Framework for Choosing a Treatment

The following stepwise approach reflects the 2023 NAMS Position Statement and the 2023 ACOG Clinical Practice Bulletin on Menopause, adapted for clinical decision-making in a telehealth context.

Step 1: Stratify by Contraindication

Ask three questions first: Does the patient have a personal history of estrogen-receptor-positive breast cancer? A history of DVT, PE, or stroke? Active liver disease?

• No to all three: Hormone therapy is the preferred first-line option for moderate-to-severe vasomotor symptoms in women aged younger than 60 or within 10 years of menopause.
• Yes to breast cancer history: Fezolinetant is the preferred non-hormonal first line; avoid paroxetine if the patient is on tamoxifen.
• Yes to thromboembolic history: Transdermal estrogen carries substantially lower thrombotic risk than oral estrogen (odds ratio 0.9 vs. 3.5 in the ESTHER study, N=881) [19], but clinical judgment and shared decision-making govern the final choice.

Step 2: Match Drug to Comorbidity

| Comorbidity | Preferred Non-Hormonal Agent | |---|---| | Breast cancer on tamoxifen | Fezolinetant, venlafaxine, gabapentin | | Depression or anxiety | Venlafaxine or paroxetine (dual benefit) | | Insomnia dominant | Gabapentin 900 mg at bedtime | | Overactive bladder co-existing | Oxybutynin (treats both) | | Hypertension on beta-blocker | Avoid clonidine (additive hypotension risk) |

Step 3: Set a 12-Week Reassessment Point

All of the non-hormonal agents show most of their efficacy by 8 to 12 weeks. If frequency has not dropped by at least 40% at 12 weeks, switch rather than layer agents. Combining an SSRI/SNRI with gabapentin is used in practice but lacks strong randomized trial support.

When Should You Worry About Hot Flashes?

Most hot flashes are benign vasomotor symptoms tied to estrogen flux. Some presentations warrant medical evaluation beyond routine menopause management.

Red-Flag Presentations

Seek evaluation if hot flashes:

• Begin before age 40 (premature ovarian insufficiency affects roughly 1% of women and carries significant cardiovascular and bone-density implications) [20]
• Occur in a man who has never taken androgen-suppressive therapy
• Are accompanied by weight loss, drenching night sweats, or lymphadenopathy (carcinoid syndrome, lymphoma, and pheochromocytoma must be excluded)
• Begin abruptly after starting a new medication (review the drug list above)

Diagnostic Workup

No single test diagnoses hot flashes. Diagnosis is clinical. The workup aims to exclude secondary causes and confirm menopausal status:

• FSH greater than 40 IU/L on two samples 4 to 6 weeks apart (in women not on combined hormonal contraception) confirms ovarian insufficiency
• TSH (thyroid dysfunction mimics hot flashes)
• 24-hour urine catecholamines or plasma metanephrines if pheochromocytoma is suspected
• 24-hour urine 5-HIAA if carcinoid is suspected

Lifestyle and Non-Drug Interventions

Drug therapy is not the only pathway. Lifestyle modifications can reduce hot flash frequency by 20 to 30% and are recommended as adjuncts in all major guidelines.

Cognitive behavioral therapy (CBT): The MENOS 2 trial (N=96) showed that a 4-session CBT protocol reduced hot flash problem rating by 1.36 points on a 10-point scale compared with 0.28 for control (P<0.001) [21]. The benefit persisted at 26-week follow-up.

Core temperature cooling: Keeping the bedroom at 65 to 68°F (18 to 20°C), wearing moisture-wicking fabrics, and using a cooling pillow reduce night-sweat burden in observational data. No randomized trial has quantified the effect precisely.

Phytoestrogens: Isoflavone supplements (40 to 80 mg/day) show modest reductions of 20 to 25% in hot flash frequency in meta-analyses, with wide heterogeneity across trials [22]. They are not recommended as a substitute for pharmacological therapy in women with severe symptoms.

Weight loss: A randomized trial (N=40) by Thurston et al. Found that a 10% reduction in body weight reduced hot flash frequency by 33% at 6 months. Adipose tissue is a secondary source of estrogen (via aromatase), and its loss paradoxically reduces the buffer against estrogen flux during menopausal transition [23].

Special Populations

Men on Androgen Deprivation Therapy

Hot flashes affect 55 to 80% of men on ADT, with the same hypothalamic mechanism as in women. Low-dose medroxyprogesterone acetate (5 to 10 mg daily), venlafaxine 75 mg, and cyproterone acetate (outside the US) all carry evidence for efficacy. Fezolinetant has not been studied in men.

Breast Cancer Survivors

This is the population where non-hormonal options carry the clearest priority. A 2023 Cochrane review (27 trials, N=5,401) found that SSRIs/SNRIs reduced hot flash frequency by 1.69 episodes per day (95% CI 1.19 to 2.19) compared with placebo in breast cancer survivors [24]. Gabapentin and clonidine showed smaller but consistent benefits.

Transgender Women

Exogenous estrogen therapy in trans women effectively eliminates hot flashes when used at adequate doses (typically estradiol maintaining levels of 100 to 200 pg/mL). Stopping or reducing estrogen for gender-affirming care procedures can precipitate vasomotor symptoms identical to those of menopause.